Abscopal effect on subcutaneously radiation therapy; and/or

Slides:



Advertisements
Similar presentations
Meredith Baker, MD PI: Bo Lu, MD – Radiation Oncology May 29th, 2014
Advertisements

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immune Response During Therapy With Cisplatin or Radiation.
Lund University, LUND Sweden
Xiaoyan Wu, M. D. , Ph. D. , Peili Chen, M. D. , Ph. D. , Stephen T
Conclusions THE ROLE OF APOPTOSIS IN PITUITARY
Fig. 1. Effects of letrozole (Let; 10 μg/day) and tamoxifen (Tam; 100 μg/day) and their combined or alternating treatment on the growth of MCF-7Ca breast.
Bertil R.R. Persson, Lund University, Lund , Sweden
Introduction Conclusions
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
Fig. 6. Knockdown of TCF-4 inhibits TCTP-induced glioma cell proliferation in vitro and in vivo. (A) TCF-4 was knocked down in U-251/TCTP and H-4/TCTP.
Molecular Therapy - Nucleic Acids
Fig. 1. Electroporation of interleukin 12 (IL-12) DNA compared with control DNA increases the level of IL-12 expression (picograms/milligrams total protein)
R E I G T T RADIO ELECTRO IMMUNO-GENE TUMOUR THERAPY
A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells
Combretastatin A-4 prodrug inhibits growth of human non–small cell lung cancer in a murine xenotransplant model  Arnd S Boehle, MD, Bence Sipos, MD, Ursula.
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
Volume 16, Issue 2, Pages (August 2009)
Clinical and Translational Radiation Oncology
Volume 31, Issue 5, Pages (November 2009)
Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 
The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death  Kwang Woon Kim, PhD, Christina K. Speirs,
Volume 15, Issue 8, Pages (August 2007)
Figure 2 Host immune responses, not the radiosensitivity
Volume 20, Issue 5, Pages (May 2012)
Volume 17, Issue 10, Pages (December 2016)
Volume 26, Issue 2, Pages (February 2018)
Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells 
Clinical and Translational Radiation Oncology
Volume 26, Issue 9, Pages (September 2018)
Volume 18, Issue 3, Pages (March 2010)
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Marrow-Derived Stromal Cell Delivery on Fibrin Microbeads Can Correct Radiation- Induced Wound-Healing Deficits  Michael W. Xie, Raphael Gorodetsky, Ewa.
Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
Volume 20, Issue 13, Pages (September 2017)
Induction of Angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis  Shinji Tanaka, Jack R. Wands, Shigeki.
AZA treatment induces a distinct gene-expression pattern in stromal cells. AZA treatment induces a distinct gene-expression pattern in stromal cells. (A-C)
Maraba Virus as a Potent Oncolytic Vaccine Vector
Volume 22, Issue 1, Pages (January 2014)
Volume 26, Issue 1, Pages (January 2018)
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma  Brynjar Mauseth, Ketil André Camilio,
Volume 31, Issue 5, Pages (November 2009)
Therapeutic delivery of rhIGF-1 reduces the severity of contact hypersensitivity responses. Therapeutic delivery of rhIGF-1 reduces the severity of contact.
Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.
Volume 8, Issue 2, Pages (August 2003)
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity  Tomer Granot,
Volume 26, Issue 4, Pages (April 2018)
Volume 20, Issue 4, Pages (April 2012)
Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.
Volume 8, Issue 3, Pages (August 2014)
Genetic Targeting of the Active Transcription Factor XBP1s to Dendritic Cells Potentiates Vaccine-induced Prophylactic and Therapeutic Antitumor Immunity 
PX-478 directly radiosensitizes tumor cells in vitro.
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus  Riikka Havunen, João M. Santos, Suvi Sorsa, Tommi Rantapero,
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells
Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.
Molecular Therapy - Methods & Clinical Development
A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.
The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.
Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.
Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.
Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.
Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.
Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.
Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.
BV6 increases bone metastasis.
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Abscopal effect on subcutaneously radiation therapy; and/or Bertil R.R. Persson1,4), Dept. Radiation Physics1), Biomedical Centre, Lund University, 221 85 LUND, Sweden

implanted tumors (N29 glioma) immunization tumor cells. Catrin Bauréus Koch1,4), Gustav Grafström1,4), Crister Ceberg1,4), Dept of Tumor Immunology2) , Dept of Neurosurgery3) Rausing Laboratory4),

in rats treated with combined Henrietta Nittby3,4), Bengt Widegren2,4) and Leif G. Salford3,4). Contact: bertil_r.persson@med.lu.se RRS 2009 Bertil_R.Persson@rmed.lu.se

The Abscopal effect was studied in a rat model with N29 glioma cells subcutaneously implanted on both hind legs of Fischer-344 rats. The exponential tumor growth rate (TGR % per day) was estimated by consecutive measurements of tumor size. The Abscopal effect was evaluated by comparing the average tumor growth rate of the unirradiated tumors in the groups of treated rats, TGRtreat , with average TGRCtrl of the corresponding tumors in the group of untreated controls. Radiation therapy (RT) was given to the right lateral tumor with 60Co gamma radiation at 4 daily fractions of 5 Gy. Immunization was performed by weekly i.p. injections of syngeneic IFN secreting N29 cells. RRS 2009 Bertil_R.Persson@rmed.lu.se

RRS 2009 Bertil_R.Persson@rmed.lu.se

RRS 2009 Bertil_R.Persson@rmed.lu.se

Controls RRS 2009 Bertil_R.Persson@rmed.lu.se

Immunotherapy RRS 2009 Bertil_R.Persson@rmed.lu.se

Radiation therapy RRS 2009 Bertil_R.Persson@rmed.lu.se

Radiation and Immunotherapy RRS 2009 Bertil_R.Persson@rmed.lu.se

RRS 2009 Bertil_R.Persson@rmed.lu.se

RRS 2009 Bertil_R.Persson@rmed.lu.se

Exponential Tumour Growth Model Tumour growth rate “TGR” is estimated from the tumour volume measurements by fitting the data of each individual tumour to a model of exponential growth where “TVt” is Tumour volume at time t t is time after first treatment. “TV0” is Tumour volume at time t = 0, “TGR” is tumour growth rate constant (% per day) RRS 2009 Bertil_R.Persson@rmed.lu.se

Tumour growth rate of subcutaneous N29 tumours: Controls and after treatment with PEF, RT, IFN immunization or their combination RRS 2009 Bertil_R.Persson@rmed.lu.se

Table I. Tumour Growth rate ”TGR” of subcutaneous tumours implanted on both Right and Left hind leg. The right tumour was treated with radiation (RT). Average of all experiments Resultat Right SE N LEFT t ctrl H t Ctrl /V t H/V Controls 8.5  0.3 40 9.1  0,3 0.1 INFg 7.6  0.6 19 9.2  0,8 0.3 0.9 RT 4.5 15 6.1  0.4 10-10 10-6 0.003 RT +INFg 5.9  0.5 7 6.4 0.002 0.0004 0,49 RRS 2009 Bertil_R.Persson@rmed.lu.se

Tumour Growth rate ”TGR” of subcutaneous tumours implanted on both Right and Left hind leg. The right tumour was treated with radiation (RT). Average of all experiments Resultat LEFT SE Right N t ctrl H t Ctrl /V t H/V Controls 9.1  0,3 8.5  0.3 40 NS INFg 9.2  0,8 7.6  0.6 19 RT 6.1  0.4 4.5 15 <0.001 <0.01 RT +INFg 6.4  0.5 5.9 7 RRS 2009 Bertil_R.Persson@rmed.lu.se

RRS 2009 Bertil_R.Persson@rmed.lu.se

RRS 2009 Bertil_R.Persson@rmed.lu.se

Specific Therapeutic Effect “STE” is defined as follow. The average of the individual Tumour growth rate constant in the group of exposed rats. day-1 The average of the individual Tumour growth rate constant in the group of control rats. day-1 RRS 2009 Bertil_R.Persson@rmed.lu.se

The STE is equal to 0 when the average of tumour growth rate constant of the exposed group, is equal to the average of the tumour growth rate constant of the control. The STE is equal to 1 when the average tumour growth rate constant of the exposed group, is equal to 0. RRS 2009 Bertil_R.Persson@rmed.lu.se

Specific therapeutic effect of subcutaneous N29 tumors after RT, Immunization with IFN and their combination RT+ IFN RRS 2009 Bertil_R.Persson@rmed.lu.se

In the present study the radiation induced abscopal effect was not significantly affected by immunization therapy, which might indicate that mechanisms other than immunogenic might be involved in the abscopal response. RRS 2009 Bertil_R.Persson@rmed.lu.se

THE END RRS 2009 Bertil_R.Persson@rmed.lu.se

RRS 2009 Bertil_R.Persson@rmed.lu.se

R I G T T RADIO IMMUNO-GENE TUMOUR THERAPY Bertil R.R. Persson PhD, MD h.c. Professor of medical radiation physics Lund University, 221 85 LUND Sweden

Abscopaleffect in subcutaneously implanted tumors (N29 glioma) in rats treated with combined radiation therapy; and/or immunization tumor cells. Abscopal effect on subcutaneously contra-lateral treatments with radiation therapy and immunization with syngeneic interferon-gamma secreting tumor cells.

Biomedical Centre, Lund University, 221 85 LUND, Sweden Bertil R.R. Persson1,4), Catrin Bauréus Koch1,4), Gustav Grafström1,4), Crister Ceberg1,4), Henrietta Nittby3,4), Bengt Widegren2,4) and Leif G. Salford3,4). Dept. Radiation Physics1), Dept of Tumor Immunology2) , Dept of Neurosurgery3) Rausing Laboratory4), Biomedical Centre, Lund University, 221 85 LUND, Sweden Contact: bertil_r.persson@med.lu.se

Radiation therapy (RT) RRS 2009 Bertil_R.Persson@rmed.lu.se

N29 tumours inoculated Subcutaneously on both sides 200 000 cells 50 000 cells Only the right tumour was irradiated RRS 2009 Bertil_R.Persson@rmed.lu.se